EU Seeks Views on Sanofi's Concessions to End Competition Probe — Update
By Edith Hancock
The European Commission is seeking feedback on a package of concessions that healthcare group Sanofi has offered to end a competition investigation into the company.
It comes after the European Union's executive arm started investigating Sanofi in June over concerns it unfairly pursued a campaign to disparage a rival flu vaccine by portraying it as inferior to its own Efluelda. Sanofi said in September 2025 the commission raided its premises over antitrust concerns.
The commission said that Sanofi offered to publish statements on its French and German websites acknowledging assessments of the vaccines carried out by the European Centre for Disease Prevention and Control and national immunisation technical advisory groups, and to avoid portraying rival CSL Seqirus's drug Fluad negatively, or claiming that Efluelda is safer or more effective. The company's commitments would be in effect until March 2030, the EU said.
"Sanofi remains confident that it has acted, and continues to act, in full compliance with all applicable laws and regulations, including competition law," a company spokesperson said, adding that Sanofi will continue to cooperate with the commission.
The regulator set an Aug. 21 deadline to receive feedback on the offer.
Write to Edith Hancock at edith.hancock@wsj.com
(END) Dow Jones Newswires
July 08, 2026 07:32 ET (11:32 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
United States